Please select the option that best describes you:
Topics:
Breast Cancer • Radiation Oncology
Does the upstaging of breast cancer based on grade and hormone receptor status in AJCC 8 change your treatment recommendations?
Is it still acceptable to deliver hypofractionation for what was previously a Stage I TN breast cancer, now Stage IIIA? Should RNI be considered? Or even concurrent chemotherapy?
Answer from: Radiation Oncologist at Academic Institution
The new stage should not in and of itself change management as the data and studies remain unchanged. Thus, for triple negative cancers, I would continue to hypofractionate if intending to treat the breast alone. In cases where I would consider RNI based on the available data (MA20 and EORTC 22922),...
Sign in or Register to read more